SMC Recommends Bosulif for the Treatment of Chronic Myeloid Leukaemia in Scotland
Following a resubmission, the Scottish Medicines Consortium (SMC) has accepted Pfizer's Bosulif (bosutinib) for use within NHS Scotland for the treatment of adult patients with chronic phase (CP), accelerated phase (AP) and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML), who have previously been treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
CML patients in Scotland will now have routine, long-term access to bosutinib. Around 60 people in Scotland were diagnosed with CML in 2012, the highest number since 2007.
Professor Mhairi Copland, Professor of Translational Haematology at the University of Glasgow said: “Today’s decision provides a treatment option for eligible CML patients whose current therapies are no longer working or are causing significant side effects. The comprehensive and pragmatic approach of the SMC in evaluating treatment, including consultation with expert clinicians and patient groups, is beginning to pay dividends for patients in Scotland.”
David Ryner, Chair/Trustee of the CML Support Group said: “This decision is fantastic news for eligible patients with chronic myeloid leukaemia in Scotland. The addition of the Patient and Clinical Engagement (PACE) group by the Scottish Medicines Consortium means that patients and clinicians now have more of a voice in these decisions and that can only be a positive thing in improving access to medicines for Scottish patients.”
In early 2014, following direction from the Scottish Government, the SMC reformed its appraisal process to improve access to medicines.
Unfortunately, elsewhere in the UK patients do not have routine access to bosutinib. Patients in Wales and Northern Ireland have no routine access to the medicine and have to prove ‘exceptional circumstances’ to even be considered.
In England, some eligible patients can access bosutinib via the Cancer Drugs Fund (CDF), however NHS England recently announced that it would remove one of the clinical uses for bosutinib from the list meaning it soon won’t be available for those specific patients.
Pfizer is calling on UK Government to take immediate action to ensure the UK has a medicines assessment system that provides patients in all four nations with routine and fair access to the innovative medicines they need.
Ben Osborn, Head of Pfizer Oncology UK, said: “We believe that the recent changes to the Scottish Medicines Consortium are a step in the right direction in improving access to oncology treatments, such as bosutinib. However, elsewhere in the UK cancer patients are still being denied access to innovative medicines. Government needs to give a clear signal for NICE reform and act immediately to ensure a fair and sustainable solution to allow greater access to innovative medicines for patients.”
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance